NEW YORK, April 11, 2014 /PRNewswire-iReach/ -- Clinilabs, an early phase and specialty CRO that provides clinical drug development services to industry, announced today the arrival of Mina Pastagia, MD, MS to the team. Dr. Pastagia has assumed the position of Medical Director and Principal Investigator at the company's Phase I unit in New York City.
Dr. Pastagia is board certified in internal medicine and infectious disease, has a Master's degree in clinical/translational sciences, and also is a registered pharmacist in the State of New York. She received her medical degree from SUNY Downstate Medical Center and her Master's degree from The Rockefeller University. Dr. Pastagia completed her internal medicine residency at Boston Medical Center, and her infectious diseases fellowship at Mount Sinai Medical Center.
Dr. Pastagia's career has focused on drug discovery, drug development, drug delivery, and patient safety. She has extensive experience as a clinician in internal medicine, and as an infectious diseases specialist who has conducted basic science research with novel compounds in the biotechnology sector. Dr. Pastagia has written several publications within the past few years, her most recent detailing the "Challenges to Conducting a Clinical Trial of Combination Therapy of Colistin and Rifampicin for Extensively Drug-Resistant Acinetobacter Baumannii". Over the past 8 years, Dr. Pastagia's role as a clinician, research scientist, and Phase I investigator, as well as her experience within private industry, have resulted in her broad skillset, which is ideally suited for a Phase I environment.
Dr. Zammit, President and CEO, states "We are very excited to bring Dr. Pastagia into our team of highly experienced and capable investigators. Her contributions will support our position as a leading provider of early phase development services, and her presence will enable us to expand both the number of scope of trials we are running at our facilities."
About Clinilabs Inc.
Clinilabs is a full-service contract research organization (CRO) that specializes in early-phase studies, from first-in-human to proof-of-concept, with normal healthy volunteers and patient populations. The company owns and operates two Phase I units in the US, and maintains a network of highly qualified investigator sites for multicenter Phase II studies Worldwide. Specialty projects, including pharmacodynamic, biomarker, cardiac safety, sleep/wakefulness, metabolic, human abuse liability, and ethnobridging are among our strengths. Clinilabs is recognized globally as a leading specialty CRO, offering an alternative to large CROs for specialty projects. For more information, please visit www.clinilabs.com.
Media Contact: Hannah DAoust, Clinilabs, 646-215-6480, email@example.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com